Nutriband Inc.

NASDAQ:NTRB

Biotechnology

Healthcare
$4.82 +22.32%

+$0.85 today

Market cap
$58.59M
Beta
1.97
P/E (TTM)
-1.8
EPS (TTM)
-$0.66
52W Low $2.80High $8.63

Volume 0.03M

Average 0.01M

NTRB Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Nutriband Inc.NASDAQ: NTRB

Stock-Based Compensation · Q1 FY2026 · quarter ended Apr 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $552.46K rose 772.1% year over year, behind the +3574.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 460.8% from the prior quarter. Over 3 fiscal years it compounded at -47.8% a year.

Context

  • Stock-based compensation amounted to 5.1% of revenue in FY2025, down 66.9 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +772.1% toward the trailing-twelve-month pace of +3574.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterApr 2026
$552.46K+460.8% QoQ
Last fiscal yearJan 2026
$104.4K-93.2% YoY
LTMApr 2026
$3.23M+3574.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+772.1%——
1 year-93.2%——
3-year CAGR-47.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
104.4K USD
Year-over-year change
-93.2%
4-year CAGR
-41.6%

Stock-Based Compensation vs competitors

How NTRB compares with its peers on the latest reported figures

  • NTRB's LTM Apr 2026 stock-based compensation of $3.23M is the 7th largest of the 9 companies compared; the peer median is $11.57M.
  • Its year-over-year change of +3574.0% is the highest of 8, against a peer median of -34.1%.
  • Stock-based compensation amounts to 179.0% of revenue for NTRB, versus a peer median of 117.7%.
NTRB Competitors Peer median
Stock-Based Compensation for NTRB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$22.45M -34.1%+7.7%33.9%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$13.93M -47.2%-30.3%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$13.11M -11.0%+88.9%—
ACETAdicet Bio, Inc.LTM Mar 2026$12.39M -37.2%-5.9%—
TCRXTScan Therapeutics, Inc.LTM Mar 2026$10.76M -2.0%+37.0%117.7%
ADAGAdagene Inc.LTM Jun 2024$7.27M —-29.1%891.4%
NTRBNutriband Inc.LTM Apr 2026$3.23M +3574.0%-47.8%179.0%
GANXGain Therapeutics, Inc.LTM Mar 2026$1.79M -31.8%+5.7%—
XBITXBiotech Inc.LTM Mar 2026$465K -90.1%-10.6%—
Peer median (excluding NTRB) $11.57M-34.1%-0.1%117.7%

Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Jan 2024
FY2024
Jan 2025
FY2025
Jan 2026
Net Income(6.18M)(4.48M)(5.49M)(10.48M)(8.23M)
Depreciation & Amortization318.26K368.96K287.72K285.05K193.8K
Deferred Income Tax00000
Stock-Based Compensation897.83K732.13K742.7K1.54M104.4K
Change in Working Capital(541.38K)(219.32K)223.22K34.09K126.81K
Accounts Receivables42.97K(41.67K)(153.97K)74.8K(44.56K)
Inventory(78.8K)(97.69K)60.73K(43.44K)94.05K
Accounts Payables(145.26K)(104.86K)198.89K23.61K120.94K
Other Working Capital(360.29K)24.9K117.57K(20.89K)(43.63K)
Other Non-Cash Items2.23M614.51K704.17K3.99M2.67M
Operating Cash Flow(2.81M)(2.99M)(3.53M)(4.63M)(5.13M)
Capital Expenditures(81.6K)(79.3K)(51.76K)(92.04K)(5.32K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(81.6K)(79.3K)000
Investing Cash Flow(81.6K)(79.3K)(51.76K)(92.04K)(5.32K)
Debt Repayment(1.63M)(17.8K)2.09M8.69M(21.62K)
Common Stock Issued6.42M02.61M8.41M5.42M
Common Stock Repurchased(104.47K)(119.01K)0(149K)0
Dividends Paid(196.59K)0000
Other Financing Activities3.14M296.88K0690
Financing Cash Flow7.63M160.07K2.09M8.54M5.4M
Effect of Forex Changes00000
Net Change in Cash4.74M(2.91M)(1.49M)3.82M263.14K
Free Cash Flow(2.89M)(3.07M)(3.58M)(4.72M)(5.13M)

Nutriband Inc.

NASDAQ:NTRB

Intrinsic Alpha fair value

Locked

Current Price

$4.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.